CYTO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 119468 min ago

@ $1.986

Išleistas: 9 vas. 2024 @ 22:25

Grąža: -18.93%

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 22:30):

Stats
Šios dienos apimtis	30 850.00
Vidutinė apimtis	1.23M
Rinkos kapitalizacija	3.61M
EPS	$0 ( 2024-04-10 )
Kita pelno data	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.0190 (1.18%)

Insider Trading

Date	Person	Action	Amount	type
2008-05-08	Carter Stephen	Sell	10 000	Common Stock
2008-05-08	Lokay Kevin G	Sell	185 439	Common Stock
2008-05-08	Lokay Kevin G	Sell	100 000	Options to Purchase Common Stock
2008-05-08	Mollica Joseph A	Sell	10 000	Common Stock
2007-11-13	Lokay Kevin G	Buy	500 000	Options to purchase Common Stock par value $0.01

INSIDER POWER
0.00
Last 33 transactions
Buy: 1 218 228 \| Sell: 315 439

Tūris Koreliacija

Ilgas: 0.17 (neutral)

Trumpas: 0.00 (neutral)

Signal:(49.699) Neutral

Altamira Therapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
PIII	0.951
PROC	0.95
DISH	0.948
LGMK	0.945
AHCO	0.944
LGHL	0.942
EVLO	0.942
TTEC	0.941
MDRX	0.941
UPC	0.94

10 Labiausiai neigiamai susiję koreliacijos
VKTX	-0.965
JMAC	-0.965
IQ	-0.96
DKDCA	-0.96
CMPO	-0.957
HHGC	-0.956
IVCP	-0.956
AIB	-0.951
OVLY	-0.951
ACLS	-0.951

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Altamira Therapeutics Koreliacija - Valiuta/Žaliavos

-0.16
( neutral )

-0.19
( neutral )

0.00
( neutral )

-0.19
( neutral )

0.21
( neutral )

-0.14
( neutral )

Altamira Therapeutics Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-14.80

FY	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-14.80

FY	2022
Pajamos:	$305 616
Bruto pelnas:	$-1.14M (-372.44 %)
EPS:	$-29.13

FY	2021
Pajamos:	$63 882.00
Bruto pelnas:	$-2.18M (-3 407.33 %)
EPS:	$-3.24

Financial Reports:

No articles found.

Altamira Therapeutics

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.